This Organon Analyst Is Bearish On Heels Of Health Care Company’s Merck Spinoff
Although management has largely delivered on the post-spin objectives, Organon & Co. (NYSE: OGN) has no pipeline assets and its financial leverage limits potential M&A to invest in future growth drivers, according to Bank of America (BofA) Securities.